To further explore the impact of EVOO on AD via NRF2 modulation, we compared the proteins associated with EVOO’s bioactive compounds to the gene targets of clinical trial drugs known to activate NRF2 (Table 2). This evidence concerns the gene NFE2L2 and Alzheimer disease.